Breaking News, Promotions & Moves

VectorY Appoints New CEO

Jim Scibetta brings more than 20 years of executive leadership experience.

Author Image

By: Charlie Sternberg

Associate Editor

VectorY Therapeutics, a biotech company developing vectorized antibody therapies for the treatment of neurodegenerative diseases, has appointed Jim Scibetta as Chief Executive Officer.   Former CEO and founder, Sander van Deventer will become President of R&D and will continue to drive the development of VectorY’s pipeline, including its lead program, VTx-002, a novel vectorized antibody targeting TDP-43 for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is currently in IND-en...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters